![Ryan Robinson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ryan Robinson
Director of Finance/CFO at Tourmaline Bio, Inc.
Ryan Robinson active positions
Companies | Position | Start | End |
---|---|---|---|
Tourmaline Bio, Inc.
![]() Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Comptroller/Controller/Auditor | 30/06/2023 | - |
Director of Finance/CFO | 30/06/2023 | - | |
Treasurer | 30/06/2023 | 18/10/2023 |
Career history of Ryan Robinson
Former positions of Ryan Robinson
Companies | Position | Start | End |
---|---|---|---|
Korro Bio, Inc.
![]() Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Treasurer | 30/06/2020 | 30/06/2023 |
Training of Ryan Robinson
Boston College | Graduate Degree |
Statistics
International
United States | 4 |
Operational
Treasurer | 3 |
Comptroller/Controller/Auditor | 2 |
Director of Finance/CFO | 2 |
Sectoral
Commercial Services | 2 |
Health Technology | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Tourmaline Bio, Inc.
![]() Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Commercial Services |
Korro Bio, Inc.
![]() Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Ryan Robinson
- Experience